Florencia Segal

Directeur/Membre du Conseil chez Antiva Biosciences, Inc.

Profil

Dr. Florencia Pereyra Segal is a Partner at MPM BioImpact.
Florencia is an Infectious Diseases physician-scientist and drug development leader.
She serves on the Board of Directors of portfolio company Antiva Biosciences.
Prior to joining MPM BioImpact, Florencia was the Global Head of Translational Medicine for Global Health at Novartis, during which time she and her team lead the early development of a broad portfolio, including small molecules and biologics for the treatment of viruses, bacteria, and parasites.
Prior to her time in industry Florencia was a Principal Investigator leading translational and laboratory research focused on HIV immunology at the Ragon Institute of MGH, MIT and Harvard.
Florencia earned her M.D.
with honors at the Universidad Central de Venezuela and completed her specialty Infectious Diseases and post-doctoral training at Brigham and Women’s and Massachusetts General Hospital.
She remains a faculty member and associate physician at the Division of Infectious Diseases at Brigham and Women’s Hospital where she has practiced for over 15 years.

Postes actifs de Florencia Segal

Sociétés	Poste	Début
MPM BioImpact, Inc	Private Equity Investor	01/11/2022
Antiva Biosciences, Inc.	Directeur/Membre du Conseil	01/04/2023

Formation de Florencia Segal

Central University of Venezuela

Doctorate Degree